Sucampo Pharmaceuticals, Inc. and Clinigen Announce Named Patient Program for European Union, Iceland and Norway to Provide Access to AMITIZA® (lubiprostone) for Chronic Idiopathic Constipation Patients

Published: Apr 18, 2012

BETHESDA, Md. & BURTON-ON-TRENT, U.K.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its wholly-owned subsidiary, Sucampo AG, has implemented a Named Patient Program (NPP) to permit access to AMITIZA (lubiprostone) for patients with chronic idiopathic constipation (CIC) in the European Union (EU), Iceland and Norway. Clinigen Global Access Programs (GAP) will manage the program and will allow healthcare professionals to prescribe lubiprostone for their patients until the time that it is approved within their countries.

Back to news